Pharmaceutical News

RSS

Investment report on Generex Biotechnology from MicroStockProfit.com

MicroStockProfit.com announces an investment report featuring Generex Biotechnology Corp. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

19 Apr 2010

Methotrexate therapy not recommended beyond 6 months after remission: JAMA

For patients with juvenile idiopathic arthritis in remission, withdrawal of treatment with the drug methotrexate over 12 months vs. 6 months did not reduce the rate of relapse, according to a study in the April 7 issue of JAMA.

19 Apr 2010

Cell Therapeutics receives feedback regarding proposed filing of MAA for pixantrone

Cell Therapeutics, Inc. today announced that it met with and received feedback from the rapporteurs and the European Medicines Agency's medical reviewers regarding a proposed filing of a Marketing Authorization Application for pixantrone in the European Union to treat relapsed/refractory aggressive non-Hodgkin's lymphoma.

19 Apr 2010

Protein Potential receives Phase II SBIR Grant to develop vaccine for prevention of P. vivax infections

Protein Potential LLC has received support from the National Institute of Allergy and Infectious Diseases of the NIH in the form of a Phase II Small Business Innovation Research Grant. The three-year award totaling approximately $3 million will support translational research to develop a vaccine for the prevention of malaria caused by the parasite Plasmodium vivax.

19 Apr 2010

Study shows long-term effect of vitamins and calcium supplements in breast cancer reduction

Vitamins and calcium supplements appear to reduce the risk of breast cancer, according to findings presented at the American Association for Cancer Research 101st Annual Meeting 2010.

19 Apr 2010

Pre-clinical data on MM-121 and MM-111 to be presented at AACR 2010

Merrimack Pharmaceuticals, Inc. announced today that it will present pre-clinical data on MM-121 and MM-111, the two lead candidates in the company's pipeline of five novel cancer antibodies, at the 101st Annual Meeting of the American Association for Cancer Research (AACR) being held April 17 – 21, 2010, in Washington, D.C.

17 Apr 2010

Honey beneficial for treatment of fungating tumor wounds

Surviving cancer is physically and emotionally exhausting. But for many patients, beating the disease itself is just the first hurdle. A second ordeal comes from living with the fungating tumor wounds that accompany various cancers. Aside from the pain they inflict, these wounds often emit a strong and offensive odor. Not only does going into public become potentially embarrassing, but it also can be extremely depressing when even close family members are repulsed by the smell.

17 Apr 2010

MedImmune to present ten abstracts at American Association for Cancer Research meeting

MedImmune today announced that ten abstracts on progress being made in various oncology programs will be presented during the Annual Meeting of the American Association for Cancer Research in Washington, DC from April 17 to 21.

17 Apr 2010

2010 to be an active year for new drug applications, says Fitch Ratings

Fitch Ratings sees an active year for new drug applications to be registered to U.S. and European drug regulators considering recent updates to the pharmaceutical industry's late-stage R&D programs. According to Fitch's new Global Pharmaceutical R&D Pipeline report, the Fitch-rated pharmaceutical developers listed in the report plan on submitting marketing applications to the U.S. Food & Drug Administration (FDA) or the European Medicines Agency (EMEA) during 2010 for approval of 22 novel drug therapies.

17 Apr 2010

MEDIHONEY dressings serve as low-cost method for treating wounds in indigent patients

Using a particular brand of medical honey dressing may be a safe, effective and low-cost method of treating chronic, non-healing wounds in indigent patients, according to a poster presented at the Symposium on Advanced Wound Care and the Wound Healing Society, an international conference drawing clinicians from all over the globe, which was held April 17-20 in Orlando.

17 Apr 2010

MEDIHONEY dressings effective in treating chronic wounds in children

Chronic, non-healing wounds can be a serious problem for children as many currently available treatment modalities can be too harsh or toxic. At the 2010 Symposium on Advanced Wound Care (SAWC) and the Wound Healing Society (WHS), an international conference drawing clinicians from all over the globe which was held April 17-20 in Orlando, two clinicians presented case series illustrating the benefits of MEDIHONEY® dressings for this challenging patient population.

17 Apr 2010

NVIC participates in NVAC-sponsored meeting to discuss the U.S. vaccine safety system

The National Vaccine Information Center participated in a meeting sponsored by the federal National Vaccine Advisory Committee and facilitated by The Keystone Center April 11-13 in Salt Lake City to discuss strengthening the U.S. vaccine safety system.

17 Apr 2010

Global Leaders Institute to host VacChina 2010 Vaccine Development Summit

Hosted by Global Leaders Institute, "VacChina 2010", a Vaccine Development Summit to be held from September 15-16, 2010, will bring together the world's major vaccine players and their respective senior level representatives to Shanghai, the heart of China's biopharmaceutical innovation.

17 Apr 2010

Wound Management Technologies' CellerateRx product to be highlighted at SAWC/WHS meeting

Wound Management Technologies, Inc. announced today that its CellerateRx product, distributed through its subsidiary Wound Care Innovations, LLC, will be highlighted in a presentation at the 23rd Annual Symposium on Advanced Wound Care and Wound Healing Society meeting April 17-20 in Orlando, Florida.

17 Apr 2010

Study shows beneficial impact of TYSABRI on QoL in MS patients

Biogen Idec and Elan Corporation, plc today announced results from a one-year, longitudinal health outcomes studys 62nd Annual Meeting in Toronto, April 10 - 17, 2010. The AAN Annual Meeting is the world's largest gathering of neurologists.

17 Apr 2010

Japanese ministry approves DIQUAS Ophthalmic Solution 3% for dry eye treatment

Santen Pharmaceutical Co., Ltd. and Inspire Pharmaceuticals, Inc. announced today that the Japanese Ministry of Health, Labour and Welfare granted approval for the new dry eye treatment drug, DIQUAS Ophthalmic Solution 3% (generic name: diquafosol tetrasodium), on April 16, 2010.

From Santen Pharmaceutical Co., Ltd. 17 Apr 2010

Treatment with high dose UDCA no more effective for NASH: German study

Results of a German study presented today at the International Liver CongressTM 2010, the Annual Meeting of the European Association for the Study of Liver in Vienna, Austria, have shown that overall, treatment with high dose (23-28mg/kg/d) ursodeoxycholic acid is no more effective than placebo in the treatment of non-alcoholic steatohepatitis, the most advanced form of non-alcoholic liver disease associated with cirrhosis of the liver.

17 Apr 2010

Strativa Pharmaceuticals: Oravig buccal tablets receive FDA approval for OPC

Strativa Pharmaceuticals today announced that the U.S. Food and Drug Administration has approved Oravig (miconazole) buccal tablets for the treatment of oropharyngeal candidiasis, more commonly known as thrush, in adults and children age 16 and older.

17 Apr 2010

Genentech's Tarceva receives FDA approval as maintenance therapy for advanced NSCLC

Genentech, Inc., a wholly owned member of the Roche Group, announced today that the U.S. Food and Drug Administration approved the daily pill Tarceva® (erlotinib) as a maintenance treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease has not progressed after four cycles of platinum-based first-line chemotherapy.

17 Apr 2010

FDA approves BioAlliance Pharma's Oravig for OPC

BioAlliance Pharma SA, a company dedicated to the treatment and supportive care of cancer and AIDS patients, announces today the approval by the US FDA of Oravig® (miconazole Lauriad®, known as Loramyc® in Europe) for the treatment of Oropharyngeal Candidiasis (OPC) in adults.

17 Apr 2010

Pharmaceutical News

Investment report on Generex Biotechnology from MicroStockProfit.com

Methotrexate therapy not recommended beyond 6 months after remission: JAMA

Cell Therapeutics receives feedback regarding proposed filing of MAA for pixantrone

Protein Potential receives Phase II SBIR Grant to develop vaccine for prevention of P. vivax infections

Study shows long-term effect of vitamins and calcium supplements in breast cancer reduction

Pre-clinical data on MM-121 and MM-111 to be presented at AACR 2010

Honey beneficial for treatment of fungating tumor wounds

MedImmune to present ten abstracts at American Association for Cancer Research meeting

2010 to be an active year for new drug applications, says Fitch Ratings

MEDIHONEY dressings serve as low-cost method for treating wounds in indigent patients

MEDIHONEY dressings effective in treating chronic wounds in children

NVIC participates in NVAC-sponsored meeting to discuss the U.S. vaccine safety system

Global Leaders Institute to host VacChina 2010 Vaccine Development Summit

Wound Management Technologies' CellerateRx product to be highlighted at SAWC/WHS meeting

Study shows beneficial impact of TYSABRI on QoL in MS patients

Japanese ministry approves DIQUAS Ophthalmic Solution 3% for dry eye treatment

Treatment with high dose UDCA no more effective for NASH: German study

Strativa Pharmaceuticals: Oravig buccal tablets receive FDA approval for OPC

Genentech's Tarceva receives FDA approval as maintenance therapy for advanced NSCLC

FDA approves BioAlliance Pharma's Oravig for OPC

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News